GB201006167D0 - Compounds for the treatment of metabolic disorders - Google Patents
Compounds for the treatment of metabolic disordersInfo
- Publication number
- GB201006167D0 GB201006167D0 GBGB1006167.9A GB201006167A GB201006167D0 GB 201006167 D0 GB201006167 D0 GB 201006167D0 GB 201006167 A GB201006167 A GB 201006167A GB 201006167 D0 GB201006167 D0 GB 201006167D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compounds
- treatment
- metabolic disorders
- metabolic
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1006167.9A GB201006167D0 (en) | 2010-04-14 | 2010-04-14 | Compounds for the treatment of metabolic disorders |
| PCT/EP2011/055865 WO2011128395A1 (en) | 2010-04-14 | 2011-04-13 | N- substituted 3-amino 4 - ( pyrrolidine - 1 - carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1006167.9A GB201006167D0 (en) | 2010-04-14 | 2010-04-14 | Compounds for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201006167D0 true GB201006167D0 (en) | 2010-05-26 |
Family
ID=42236249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1006167.9A Ceased GB201006167D0 (en) | 2010-04-14 | 2010-04-14 | Compounds for the treatment of metabolic disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201006167D0 (en) |
| WO (1) | WO2011128395A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103958495B (en) | 2011-06-09 | 2018-06-22 | 理森制药股份公司 | The compound of conditioning agent as GPR-119 |
| JP2015522080A (en) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN113248416B (en) * | 2020-02-10 | 2024-03-26 | 江西博腾药业有限公司 | Preparation method and application of 1- ((benzyloxy) carbonyl) -4-ethylpyrrolidine-3-carboxylic acid |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| JP4958560B2 (en) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Heterocyclic derivatives as GPCR receptor agonists |
| EP1838311A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| JP5065908B2 (en) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | G protein-coupled receptor agonist |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| JP2008545010A (en) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | G protein-coupled receptor agonist |
| BRPI0613505A2 (en) | 2005-06-30 | 2011-01-11 | Prosidion Ltd | gpcr agonists |
| BRPI0710839A2 (en) | 2006-04-06 | 2011-08-23 | Prosidion Ltd | heterocyclic gpcr agonists |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| US20100048632A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine GPCR Agonists |
| CL2008000017A1 (en) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE |
| AR064735A1 (en) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| WO2008157330A1 (en) | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| WO2009014910A2 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
| WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| KR101136774B1 (en) | 2007-10-18 | 2012-04-19 | 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 | Metal covered polyimide composite, process for producing the composite, and process for producing electronic circuit substrate |
| US20090270404A1 (en) * | 2008-03-31 | 2009-10-29 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| GB0812031D0 (en) | 2008-07-01 | 2008-08-06 | 7Tm Pharma As | Thiazole derivatives |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| EP2321308B9 (en) | 2008-07-10 | 2012-08-08 | Prosidion Limited | Piperidine gpcr agonists |
| CN102083813A (en) | 2008-07-10 | 2011-06-01 | 普洛希典有限公司 | Piperidinyl gpcr agonists |
| GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0904287D0 (en) * | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) * | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
-
2010
- 2010-04-14 GB GBGB1006167.9A patent/GB201006167D0/en not_active Ceased
-
2011
- 2011-04-13 WO PCT/EP2011/055865 patent/WO2011128395A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011128395A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| KR102297388B9 (en) | Use of akkermansia for treating metabolic disorders | |
| GB0904285D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| GB2503852B (en) | Compounds for the treatment of neuropsychiatric disorders | |
| ZA201107446B (en) | Compounds for the treatment of metabolic disorders | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL225896A0 (en) | Treatment of mecp2-associated disorders | |
| IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| BR112013015048A2 (en) | composition for the treatment of metabolic disorders | |
| HUE036285T2 (en) | Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac | |
| GB201006167D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL234616A0 (en) | Herbal composition for the treatment of metabolic disorders | |
| GB201006166D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL234796B (en) | Compounds for the treatment of ischemia-reperfusion-related diseases | |
| EP2240024A4 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004744D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004742D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004741D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201004740D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201019482D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201006164D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201006163D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201106154D0 (en) | Compounds for the treatment of metabolic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |